Reductions in log P Improved Protein Binding and Clearance Predictions Enabling the Prospective Design of Cannabinoid Receptor (CB1) Antagonists with Desired Pharmacokinetic Properties-Reference-Cited by-同舟云学术

Reductions in log P Improved Protein Binding and Clearance Predictions Enabling the Prospective Design of Cannabinoid Receptor (CB1) Antagonists with Desired Pharmacokinetic Properties

Published:2013-11-20 Issue:23 Volume:56 Page:9586-9600
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ellsworth Bruce A.¹,Sher Philip M.¹,Wu Ximao¹,Wu Gang¹,Sulsky Richard B.¹,Gu Zhengxiang¹,Murugesan Natesan¹,Zhu Yeheng¹,Yu Guixue¹,Sitkoff Doree F.¹,Carlson Kenneth E.¹,Kang Liya¹,Yang Yifan¹,Lee Ning¹,Baska Rose A.¹,Keim William J.¹,Cullen Mary Jane¹,Azzara Anthony V.¹,Zuvich Eva¹,Thomas Michael A.¹,Rohrbach Kenneth W.¹,Devenny James J.¹,Godonis Helen E.¹,Harvey Susan J.¹,Murphy Brian J.¹,Everlof Gerry G.¹,Stetsko Paul I.¹,Gudmundsson Olafur¹,Johnghar Susan¹,Ranasinghe Asoka¹,Behnia Kamelia¹,Pelleymounter Mary Ann¹,Ewing William R.¹

Affiliation:

1. Research and Development, Bristol-Myers Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm4010835

Reference35 articles.

1. The endocannabinoid system as a target for therapeutic drugs

2. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

3. Chemically Distinct Ligands Promote Differential CB1Cannabinoid Receptor-Gi Protein Interactions